CRBP Projected Dividend Yield
Corbus Pharmaceuticals Holdings Inc ( NASDAQ : CRBP )Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. Co.'s pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGF? expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. 21 YEAR PERFORMANCE RESULTS |
CRBP Dividend History Detail CRBP Dividend News CRBP Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |